James M. Frates, Chief Financial Officer at Amylyx Pharmaceuticals, Inc. (AMLX), sold 32,500 shares at $26.93 ($876K) on 2023-05-16, disclosed to the SEC on 2023-05-18.
Scheduled sale ($876k) by Chief Financial Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $26.93 | 32,000 | $862K | 98.4% |
| 2 | $27.60 | 500 | $14K | 1.6% |
| Total | $26.94 avg | 32,500 | $876K | 100% |
| Filing → |
| AMLX | SELL | 2026-02-04 | $52K | — | Filing → |
| AMLX | SELL | 2026-01-08 | $37K | — | Filing → |
| AMLX | SELL | 2025-10-02 | $309K | — | Filing → |